Aims What the best strategy is for nonculprit lesions in ST-elevation myocardial infarction (STEMI) patients presenting with multivessel disease remains a clinical dilemma. Based on recent clinical studies suggesting that complete revascularization in the acute phase is beneficial, the European Society of Cardiology and American College of Cardiology/American Heart Association guidelines have been recently changed from class 3 discouragement to a class 2B recommendation concerning the treatment of the nonculprit lesions in the acute index procedure. However, in these recent studies, nonculprit lesion treatment was guided by angiography, which is known for its poor accuracy in determining ischemia. Fractional flow reserve (FFR) guidance for treatment of nonculprit vessels seems to be a reasonable approach, and in the acute setting of STEMI, it is not yet investigated. The COMPARE-ACUTE trial aims to investigate FFR-guided complete revascularization in comparison to a culprit lesion treatment-only strategy in STEMI patients with multivessel disease presenting for primary percutaneous coronary intervention.
Conclusion
The aim of the COMPARE-ACUTE trial is to assess whether FFR-guided complete revascularization in the acute setting is superior to culprit lesion treatment-only therapy. (Am Heart J 2017;186: 21-8.) In 40% to 60% of patients presenting with acute ST-elevation myocardial infarction (STEMI), additional angiographic severe (N50% diameter stenosis) lesions are found in nonculprit vessels. 1, 2 These patients with multivessel disease have a worse survival outcome after primary percutaneous coronary intervention (PCI) compared with patients with single-vessel disease. They often undergo more revascularizations than the latter, and studies have shown that this particular patient population has a higher rate of post-myocardial infarction heart failure and suffers more frequently from electrical instability.
Cardiology and American College of Cardiology/American Heart Association guidelines discouraged the treatment of nonculprit vessels in the acute phase. However, these recommendations were mainly based on outdated and retrospective studies with their known limitations. Since then, the use of second-generation drug-eluting stents and new antithrombotic and anticoagulant drug regimens has considerably improved the outcome of primary and elective PCI. [4] [5] [6] Furthermore, in the last decade, small prospective randomized studies have shown results that point in the direction of better outcome for patients with multivessel disease treatment in contrast to retrospective registry studies. [7] [8] [9] [10] The recent prospective randomized trials such as PRAMI and CvLPRIT indicate that complete acute revascularization gives a beneficial clinical outcome compared with revascularization of the culprit lesion only. 11, 12 Furthermore, the DANAMI-3-PRIMULTI trial indicates that fractional flow reserve (FFR)-guided complete revascularization in the staged phase is also better than a culprit lesion-only strategy. 13 Altogether, these 3 studies show a reduced relative risk of between 45% and 65% for the primary end point: the cumulative of all-cause mortality, nonfatal myocardial infarction, and any revascularization. Only the PRAGUE-13 trial, which compared staged angiography--guided complete revascularization with a culprit lesiononly strategy, did not find an advantage of complete multivessel PCI. 14 In all the above-mentioned studies, multivessel disease in the control group was treated conservatively with standard guideline-based medical therapy. ""In none of the studies, FFR was used to assess lesion severity in the acute setting, therefore requiring additional assessment of ischemia at a later stage by stress tests and/or recatheterizations and FFR measurements necessitating rehospitalizations or extended admissions and additional risks.
Based on the above-mentioned trials, European Society of Cardiology and American College of Cardiology/American Heart Association guidelines changed the long-standing recommendation that in patients with multivessel disease, primary PCI should be directed only at the culprit lesions, with decisions about PCI of nonculprit vessels guided by clinically relevant ischemia objectified with stress testing and imaging at later follow-up, to a class 2B recommendation of allowing PCI of nonculprit lesions at the time of primary PCI in selected patients. [15] [16] [17] [18] Although both guideline committees did not define the qualifications of these selected patients, they describe that routine multivessel PCI should not be endorsed and that clinical patient and lesions characteristics should be integrated in the decision model.
Fractional flow reserve
Fractional flow reserve-guided revascularization has become the criterion standard for in-catherization laboratory assessment of flow-limiting lesions in patients with stable angina. 19, 20 The recent FAME trial showed that FFR-guided revascularization significantly reduces the frequency of the composite of death, nonfatal myocardial infarction, and repeat revascularization in patients with multivessel disease compared with angiography-guided revascularization. Furthermore, the use of FFR significantly reduces treatment costs and duration of hospitalization. 21 Another recent study has shown that FFR is safe and reliable at localizing relevant flow-limiting lesions in nonculprit vessels during primary PCI in acute STEMI patients as well as in staged procedures. 22 Taking the conditions described above in account, we assume that complete revascularization of all flow-limiting lesions assessed by FFR during the primary intervention will lead to a better short-and long-term clinical outcome in patients with multivessel disease. We expect a more desirable improvement of left ventricular function, a lower number of repeat revascularizations with the additional benefits of shorter and less frequent hospitalizations, and lower health care costs. Furthermore, we expect a better judgment at heart team discussions after the primary PCI in case of complex or extensive multivessel disease. Finally, the patient will leave the catheterization laboratory with a more comfortable feeling knowing that all flow-limiting lesions have been treated.
In this article, the study design and rationale of the COMPARE-ACUTE trial are described, in which the following question is addressed: does FFR-guided complete revascularization of all flow-limiting lesions in the nonculprit vessels performed within the same procedure or same hospitalization result in better clinical outcomes compared with culprit-only revascularization with residual staged revascularization driven by prove of ischemia or residual angina complaints?
Study objectives and design
The COMPARE-ACUTE study is an investigator-initiated, prospective multicenter randomized controlled trial in which 885 STEMI patients with multivessel disease between July 2011 and October 2015 were randomized. All 24 participating centers, located in Europe and Asia, are listed by country in Table I . The primary objective of this study is to assess clinical differences between FFR-guided complete revascularization in the acute setting vs culprit lesion-only revascularization.
All patients between 18 and 85 years old who presented with acute STEMI within b12 hours from onset of symptoms and with an indication for primary PCI were eligible for enrollment if in the non-infarct-related arteries (nonIRAs)-or its major side branches of ≥2.0 mm in diameter-nonculprit lesions were seen that had an angiographic stenosis of ≥50% by quantitative coronary angiography (QCA) or visual assessment and judged feasible for treatment with PCI by the operator. Nonculprit lesions were those lesions that were identified by the operator as lesions not responsible for the acute myocardial infarction, based on electrocardiogram and angiographic appearance.
The inclusion and exclusion criteria are listed in Table II .
Informed consent and randomization procedure
Informed consent was obtained before the procedure according to Good Clinical Practice guidelines. Oral approval in the presence of a third independent person (who is not involved in the study) before or during the primary PCI procedure, followed by a signature after the procedure, was also accepted to avoid further treatment delay.
After successful and uncomplicated primary PCI treatment of the culprit lesion with an everolimus-eluting stent, the eligible patients with informed consent underwent randomization and subsequently FFR measurements in nonculprit vessels containing lesions with an angiographic stenosis of ≥50%. Only hemodynamically stable patients with nonculprit lesions judged feasible for FFR and PCI were eligible to be randomized.
Patients were randomized in a 1:2 fashion by closed and opaque randomization envelopes toward FFR-guided complete revascularization or culprit lesion-only treatment. A flowchart of the trial is shown in Figure 1 .
Fractional flow reserve measurement
Obstruction sites of 50% or more were identified during angiography by visual estimation or by QCA. Using a commercially available pressure wire (St Jude Medical, St Paul, MN), Pa/Pd ratio was measured at rest and during maximally induced hyperemia achieved by intravenous (140 μg kg −1 min −1 ) or repeated dose-increasing intracoronary adenosine bolus injections (40-100 μg for the right coronary artery and 60-100 μg for the left coronary artery). Operators were advised to inject contrast after the adenosine bolus injections under fluoroscopy, to check if all intracoronary injections were selectively given.
The adenosine protocol is presented in the supplementary appendix.
Fractional flow reserve-guided complete revascularization group
In the FFR-guided group, the FFR measurements were used to guide the decision for percutaneous revascularization. Percutaneous coronary intervention and stenting with an everolimus-eluting stent of nonculprit vessels took place in all flow-limiting lesions (FFR ≤0.80), generally during the same intervention. In case of complex flow-limiting lesions and/or logistic problems, additional PCI of the nonculprit vessels could be delayed at the operator's discretion, but had to be performed during the index hospitalization and preferably within 72 hours after the primary PCI.
Culprit lesion-only treatment group
In the culprit lesion-only group, the procedure stopped after the FFR measurements. The patient was referred back to his treating cardiologist in the clinic and/or outpatient clinic, who was a different physician than the interventional cardiologist that performed the PCI. Both the patient and his treating cardiologist were blinded for the FFR measurements but not for the angiographic imaging. The values of the FFR measurements were not reported in the PCI report or discharge letter but were registered in the study database only.
The treating cardiologist could decide whether a later staged revascularization of nonculprit vessels was needed based on ischemia detecting tests or symptoms. If any revascularization was needed and done within 45 days from the primary intervention in an elective clinically indicated setting, this would not count as an event according to the study protocol. Only urgent revascularizations within 45 days after the index procedure were counted as events. Additional patient management, including anticoagulant and antithrombotic regimens, was done in accordance with contemporary guidelines.
Primary and secondary end points
The primary end point is defined as the composite of all-cause mortality, nonfatal myocardial infarction, any revascularization, and cerebrovascular events (major adverse cardiac and cerebrovascular events) at 12 months between the FFR-guided complete revascularization group and the culprit-only group.
Secondary end points include the following: infarction, any revascularization, stroke, and major bleeding at 12, 24, and 36 months (ie, net adverse clinical events) between the FFR-guided complete revascularization group and the culprit-only group 6. The composite of hospitalization for heart failure and unstable angina pectoris at 12, 24, and 36 months between the FFR-guided complete revascularization group and the culprit-only group 7. All-cause mortality or myocardial infarction at 12, 24, and 36 months 8. Any revascularization at 12, 24, and 36 months 9. Stent thrombosis at 12, 24, and 36 months 10. Bleeding at 48 hours and 12 months 11. Treatment costs at 12, 24, and 36 months between the FFR-guided complete revascularization group and the culprit-only group
Statistical considerations
We have made our estimations for the FFR-guided acute PCI subgroup based on data from the COMPARE trial 4 Therefore, the event rate of all-cause mortality, nonfatal myocardial infarction, and revascularization is estimated at 7% at 12 months. Counting an additional rate of 1% for stroke, a primary end point of 8% is expected.
In the culprit-only group, we have based our estimations on the combined experience of all participating centers. Therefore, the following assumptions are made: 60% of patients will receive an exercise stress test, 20% will receive a nuclear scan, and 20% will receive no ischemia-detecting test but will be guided by clinical symptoms and angiographic data. Furthermore, we assume that the decision to revascularization will be taken in 70% of patients with positive FFR, whereas the decision to not perform revascularization will be taken in 50% of patients with negative FRR.
Based on the results of the FAME study, we expect a lesion with N50% stenosis to have an equal distribution of FFR-negative and FFR-positive patient. 4, 23 For the culprit-only FFR-positive subgroup that will receive optimal medical treatment only, we expect an event rate of 20%. For the culprit-only FFR-positive and FFR-negative subgroups that will receive revascularization procedures, we expect an event rate of 16%, mainly because of periprocedural myocardial infarction and revascularization procedures beyond the 45-day period postindex procedure resulting in an expected overall event rate of 14.6% in the culprit-only arm (Supplementary Figure, graphical presentation of the power calculation).
We calculated a sample size of 858 patients to be sufficient to obtain a power of at least 80% with a 2-sided false-positive α level of 5% for rejecting the null hypothesis of no difference when the end point difference is 8% in the FFR-guided group vs 14.5% in culprit-only group. Considering a 3% loss in follow-up, a total of 885 patients need to be randomized in this trial.
Categorical variables will be evaluated with the use of χ 2 or Fisher exact test, whereas continuous variables will be evaluated with the Wilcoxon rank sum test. The results in both groups for the primary and secondary end points will be presented as Kaplan-Meier curves. Although the trial was designed in a 1:2 randomization for the purpose of subgroup analyses, all these secondary end points will not have sufficient power and the results will be hypothesis generating.
Ethical considerations
The steering committee consists of 5 cardiologists who supervise the trial. The data safety monitoring 
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Outcome in subgroups according to study protocol.
board (DSMB) consists of 3 members from Gothia Forum (Gothenburg, Sweden) who will advise on the interim safety and event reports. For ethical reasons, 3 formal interim analyses were performed and reviewed by DSMB for safety and end point consistency. If each of the 2 patient groups is associated with increased mortality, premature termination of the trial was to be considered. The first 5 patients in all centers were fully monitored for all variables; thereafter, random monitoring was performed. All reported events are monitored.
Events will be analyzed by an independent clinical research organization (Diagram, Zwolle, the Netherlands) and will be adjudicated by an independent clinical evaluation committee.
All sites underwent training before study initiation, involving how to obtain informed consent, how to perform randomization, data entry, guidewire-based coronary pressure measurement, and how to complete the electronic case record.
No members of the clinical evaluation committee, clinical research organization, or DSMB participated in recruitment or data collection or had access to any information regarding treatment allocations.
Follow-up
Follow-up took place by outpatient clinic visits on 30 days and 12, 24, and 36 months after primary revascularization or by mail and telephone in case no outpatient clinic visit was scheduled.
Discussion
What to do with the nonculprit lesions in multivessel disease STEMI patients remains a vexing problem. Recent trials, such as PRAMI and CvLPRIT, have changed the long-standing view off a conservative approach to an aggressive strategy in which in the acute phase, the angiographic significant appearing nonculprit lesions need to be treated besides the lesions responsible for the STEMI. 11, 12 Whether all these angiographic significant non-infarct-related lesions actually need to be treated and at what time point remains unclear. Angiography is not the best method in detecting whether nonculprit lesions are hemodynamically important or responsible for late adverse events. Fractional flow reserve has shown to be a more reliable method for detecting flow-limiting lesions. 19, 23 Therefore, incorporating FFR measurements of nonculprit lesions in multivessel STEMI patients seems to be a logical step. The rationale of the COMPARE-ACUTE trial is to explore the safety and efficacy of FFR-guided multivessel PCI in STEMI patients in the acute phase. This approach has never been investigated before and tries to answer the following questions: Is an FFR-guided acute complete strategy better compared with the conservative culprit-only strategy? Is FFR in the acute phase of primary PCI feasible and safe and how often are the nonculprit lesions flow limiting? Other features that make the COMPARE-ACUTE trial unique are as follows: the largest sample size of the multivessel PCI strategy trials at this point and the blinded FFR measurements in the culprit-only arm, which allow us to investigate the long-term outcome of FFR-negative and FFR-positive nonculprit lesions in multivessel STEMI patients. Furthermore, in comparison with the recent published DANAMI-3-PRIMULTI trial, 13 the COMPARE-ACUTE trial investigates FFR guidance in the acute phase, which might prevent staged PCI procedures as per protocol was defined in the PRIMULTI trial. Lastly, although PRAMI and CvLPRIT clearly showed benefit of complete revascularization in the acute phase of STEMI, this approach is not yet widely adopted in daily practice and guidelines. 24 Within the PRAMI and CvLPRIT trial design, an inherent flaw was present. All additional revascularizations done in the culprit-only arm were considered as an event. This does not reflect good clinical practice according to the guidelines, in which additional revascularizations is advised in case of proven ischemia, viability, or spontaneous symptoms. 15 Therefore, these trials had by design a high possibility of a positive outcome for the complete revascularization arm. The COMPARE-ACUTE trial allowed a period of 45 days after primary PCI for additional elective revascularizations in the culprit-only arm. In that respect, the COMPARE-ACUTE trial has the potential to give additional and more clinically relevant support to perform complete revascularization of flow-limiting nonculprit lesions in the acute phase.
Summary
The COMPARE-ACUTE study is a prospective, multicenter randomized controlled trial based in Europe and Asia in which 885 patients were included. This trial will assess if FFR-guided complete revascularization of STEMI patients with multivessel disease gives a better clinical outcome than the culprit lesion-only strategy. Inclusion has ended in October 2015 and conclusion of the primary end point is expected in March 2017.
